LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Human natural regulatory CD4(+) T cells comprise 5-10% of peripheral CD4(+)T cells. They constitutively express the IL-2Ralpha-chain (CD25) and the nuclear transcription Foxp3. These cells are heterogeneous and contain discrete subsets with distinct phenotypes and functions. Studies in mice report that LAG-3 has a complex role in T cell homeostasis and is expressed in CD4(+)CD25(+) T regulatory cells. In this study, we explored the expression of LAG-3 in human CD4(+) T cells and found that LAG-3 identifies a discrete subset of CD4(+)CD25(high)Foxp3(+) T cells. This CD4(+)CD25(high)Foxp3(+)LAG-3(+) population is preferentially expanded in the PBMCs of patients with cancer, in lymphocytes of tumor-invaded lymph nodes and in lymphocytes infiltrating visceral metastasis. Ex vivo analysis showed that CD4(+)CD25(high)Foxp3(+)LAG-3(+) T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-beta1, but not IL-2. An in vitro suppression assay using CD4(+)CD25(high)LAG-3(+) T cells sorted from in vitro expanded CD4(+)CD25(high) regulatory T cells showed that this subset of cells is endowed with potent suppressor activity that requires cell-to-cell contact. Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LAG3 can positively induce Treg cell activation and stimulate its immunosuppressive function [325, 326].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [326]
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173 · cited 1×
“Two subsets of induced Treg cells have been described and are shown to also exist in humans: Tr1 cells, which secrete high levels of IL-10 and arise from CD4 T cells upon encountering Ags in a tolerogenic environment (1), and Th3 cells, which are induced by oral Ag administration and secrete high levels of TGF-b1 (2).”
Background
Cited by
Items 301–350 of 350
Regulatory T Cells: Their Role, Mechanism of Action, and Impact on Cancer
Cillo, A. R., & Vignali, D. A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_6 · Cited by 1
Regulatory T Cells in Colorectal Cancer
Jafariniaorcid, M., Lotfiorcid, N., Ganjalikhani-hakmiorcid, M., & Rezaei, A. (2018) · Immunoregulation · doi:10.32598/immunoregulation.1.1.5 · Cited by 2
“Recently, the origin and phenotypic features of Treg infiltrating human tumors have been a matter of debate [39, 40] and although rapid progress have been made in our understanding of how Treg work, many conditions of their interactions with the tumor and other immune or non-immune cells remain ambiguous [41, 42].”
BackgroundImmune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer
Kapoor, S., & Padwad, Y. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-63369-1_15 · Cited by 1
Checkpoint inhibition in the fight against cancer: NK cells have some to say in it
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., & Gonzalez, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00013-8 · Cited by 1
DOW, S. W., & Guth, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00014-1 · Cited by 3
Chocarro, L., Blanco, E., Arasanz, H., Rubio, L. F., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Piñeiro, S., Vera, R., et al. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-12446 · Cited by 1
LAG-3 Role in Inflammatory Diseases
Chocarro, L., Blanco, E., Arasanz, H., Rubio, L. F., Echaide, M., Garnica, M., Ramos, P., Piñeiro, S., Kochan, G. T., & Escors, D. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-12447 · Cited by 1
LAG-3 Role in Cardiovascular Diseases
Chocarro, L., Blanco, E., Arasanz, H., Rubio, L. F., Echaide, M., Garnica, M., Ramos, P., Piñeiro, S., Kochan, G. T., & Escors, D. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-12448 · Cited by 1
LAG-3 Role in Neurological Diseases
Chocarro, L., Blanco, E., Arasanz, H., Rubio, L. F., Echaide, M., Garnica, M., Ramos, P., Piñeiro, S., Kochan, G. T., & Escors, D. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-12449 · Cited by 1
Elucidating the role of regulatory T cells in colorectal cancer progression
Besneux, M. (2015) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 2
Strecker, M. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68021
An, Z., Hsu, M. A., Gicobi, J. K., Xu, T., Harrington, S. M., Zhang, H., Pavelko, K. D., Hirdler, J. B., Lohse, C. M., Nabavizadeh, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.10.507426 · Cited by 1
Integrated germline and somatic features reveal divergent immune pathways driving ICB responsePreprint
Sears, T. J., Pagadala, M. S., Castro, A., Lee, K.-H., Kong, J., Tanaka, K., Lippman, S. M., Zanetti, M., & Carter, H. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.12.575430 · Cited by 1
Roy, S., Proffer, M. L., Syed, F., Smithmyer, M. E., Sharma, A. R., Twoy, A., Soohoo, E., Rana, J., Spaeth, J. M., Meyer, E. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.705171 · Cited by 1
“LAG-3 (CD223) is a co-inhibitory receptor expressed by CD4+CD25+CD127lo regulatory T (Treg) cells and other regulatory immune cell subsets [28, 29].”
Melanoma Immunomodulation: A War of Attrition
Doonan, B. P., Jessica, D. R. J. D. R., & Haque, A. (2011) · InTech eBooks · doi:10.5772/18669
González, N. E. H., & Pantoja, G. G. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
T Regulatory Cells – Friends or Foes?
Lindqvist, C. A. (2010) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 2
OVERCOMING SELF-REACTIVITY THROUGH IMMUNOLOGICAL AND METABOLIC REDOX MODULATION
Delmastro-Greenwood, M. M. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Halvorsen, E. C. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0364674
“Additionally, the tumour may evade 17 immune detection by production of microenvironment-derived soluble immune suppressive factors (TGFβ, IL-10, IDO), by promoting T cell exhaustion and expression of inhibitory receptors (PD-1/PD-L1, CTLA-4, LAG-3, TIM3), and by recruitment of suppressive immune cells (Tregs, M2 macr…”
Intrinsic Mechanisms Regulating T Cell Tolerance in Autoimmune Diabetes
Zhang, Q. (2018) · D-Scholarship@Pitt (University of Pittsburgh)
Current Advances in Immuno-oncology for Head and Neck Cancer
Devlin, M.-J., & Forster, M. D. (2017) · International Journal of Head and Neck Surgery · doi:10.5005/jp-journals-10001-1340
Role of Immune Inhibitors in Ovarian Cancer
Lu, H., Gu, F., & Wang, F. (2019)
Regulatory T Cells: Promises and Challenges
Alhaddad, J. B., Melhem, G., Allos, H., & Azzi, J. R. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00292-0
LAG3 expression profile and the mechanisms regulating LAG3 expression and function
Graydon, C. G. (2021) · Mspace (University of Manitoba) · Cited by 1
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Myers, J. W., Peoples, G. E., & Clifton, G. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_6 · Cited by 1
Lymphocyte Activation Gene 3 (LAG-3)
Sunshine, J. C., & Lipson, E. J. (2014) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_136-1
Regulatory T Cells - New Insights
He, X. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.98075
PD-L1/PD-1 Blockade Immunotherapy: Mechanism of response and resistance
Chocarro, L., Blanco, E., Arasanz, H., Rubio, L. F., Bocanegra, A., Garnica, M., Echaide, M., Martín‐Ramos, P., Piñeiro, S., Zuazo, M., et al. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-12445
Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral
Neira, G. C. G., Prieto, S. D. S., & Lagos, S. M. R. (2023) · CIENCIA EN DESARROLLO · doi:10.19053/01217488.v14.n2.2023.15041
Other Immune Checkpoint Targets of Interest
Csizmar, C. M., & Ansell, S. M. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch12
TURKDONMEZ, I., Şahın, E., & Sahin, M. A. (2024) · Turkish Journal of Immunology · doi:10.4274/tji.galenos.2024.07078
LAG-3 in Cancer Immunotherapy: A Comprehensive Review
Tathe, P. R., Charhate, K. B., Laddha, P. R., & Sitaphale, G. R. (2024) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-19504
Emerging therapeutics in the treatment of chronic respiratory disorders
Gupta, D., Shingte, R. D., & Suares, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-27345-2.00003-5
Васильевич, Б. Е., Ostanin, A., & Chernykh, E. R. (2025) · Archive of oncology · doi:10.2298/aoo241217003b
Buszko, M., Jones, M., Chempati, S., Morina, L., Ward, K., Habte, H. H., Dziegielewski, M., & Shevach, E. M. (2025) · Oncotarget · doi:10.18632/oncotarget.28752 · Cited by 1
“…receptor family superfamily [6] (TNFRSF) including TNFR2 [7], GITR [8], OX-40 [9], and 4-1BB [10, 11], chemokine receptors (CCR4 [12], CCR8 [13]) and co-inhibitory receptors (CTLA-4 [14–17], PD-1 [18, 19], LAG-3 [20], and Tim-3 [21]) appear to have enhanced expression on intra-tumoral T reg.”
Васильевич, Б. Е., Vasilchenko, P. V., & Chernykh, E. R. (2025) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20250503
Epigenetic activation of CD274/PD-L1 by the MSL complex expands its role beyond dosage compensation
Wen, A., Feng, X., Li, Y., Cui, X.-L., Zou, Q., Cai, Y., Jin, J., & He, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711451 · Cited by 2
Zarrinrad, G., Burkhardt, L.-M., Wagner, D. L., Schlickeiser, S., Stein, M., Wendering, D. J., Ehlen, L., Kurgan, G., Durek, P., Heinrich, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693159
Zhang, Y., zhang, L., Sun, H., Liu, Y., Xu, J., Huang, H., Fu, J., Zhang, D., Tian, T., Zhao, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16650296
Talvard-Balland, N. (2020) · theses.fr (ABES) · doi:10.70675/c97ca95bz9e5az4b51z9511zb52baa5010a2
Deluce, N. K.-N. (2019) · theses.fr (ABES) · doi:10.70675/ee25faf6za45bz4bbfzb67fzc8a5a7712c63
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3 · Cited by 1
Bonnin, E. (2022) · theses.fr (ABES) · doi:10.70675/fd80c953z7ef5z4ff7z8413z3bd284faeed4
Amirian, N., Squires, A. M., Azanabor, L., Walker, C. A., Simmonds, M. J., & Rinaldi, C. R. (2026) · Cancers · doi:10.3390/cancers18111808
“These cells can suppress activated immune cells through IL-10 production, highlighting the impact of LAG-3 on manipulating tumour immune responses [155,156].”
Zhou, P., Wang, D., Zhang, H., Zhang, F., Li, Z., & Xi, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1882680
Regulatory T cell heterogeneity: who they are, where they come from, and where they go
Yang, F., Ikeda, Y., Guo, Z., & Bednar, K. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1929923
NEGATIVE REGULATION OF REGULATORY T CELLS BY MYELOID-DERIVED SUPPRESSOR CELLS IN CANCER
Centuori, S. M. (2011) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C.
- Affiliations
- Unit of Immunotherapy of Human Tumors
- Immutep S.A., Faculté de Pharmacie , Chatenay-Malabry,
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Camisaschi, Chiara
- Casati, Chiara
- Rini, Francesca
- Perego, Michela
- Parmiani, Giorgio
- Rivoltini, Licia
- Castelli, Chiara
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-01
- Volume
- 184
- Issue
- 11
- Pages
- 6545-6551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147968481
- Cited by
- 350
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 30 · 2023: 21 · 2022: 46 · 2021: 36 · 2020: 35 · 2019: 29 · 2018: 22 · 2017: 16 · 2016: 17 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- LAG-3, regulatory T cells, Foxp3, CD4+CD25high T cells, tumor-infiltrating lymphocytes, metastasis, immunosuppression, IL-10, TGF-β1, suppressor activity, cell-cell contact, tumor immunology, T cell subsets
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Cell Separation, Flow Cytometry, Humans, Lymphocyte Activation, Neoplasms, Antigens, CD, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.